MTOR and hypophosphatemia: Supplementation for mTOR inhibitor-induced hypophosphatemia is recommended when the phosphate level is < 0.81 mmol/L (2.5 mg/dl), with oral administration for mild and moderate hypophosphatemia and intravenous administration for severe hypophosphatemia (Table 3) [35].